Drug intelligence / Profile preview

metronidazole + miconazole

Development stage
Phase 2
Lead developer
Bayer
Modality
Small Molecules
Administration
Vaginal, Topical
01

Overview

Metronidazole + miconazole is a fixed-dose combination of two small molecule drugs used primarily for the treatment of vaginal and skin infections caused by mixed bacterial and fungal pathogens. Metronidazole is an antibiotic that exerts its effect by damaging the DNA of bacteria and certain protozoa, leading to cell death. Miconazole is an antifungal agent that inhibits the synthesis of ergosterol, a key component in fungal cell membranes, thereby disrupting membrane integrity and inhibiting fungal growth. This combination provides broad-spectrum coverage against both anaerobic bacteria (via metronidazole) and fungi (via miconazole), making it effective for conditions such as bacterial vaginosis with concurrent candidiasis or other mixed infections[1][4][6]. The combination is available in various formulations including vaginal suppositories and creams.

Brand names
Metromicon-NeoKlion-D 100Klion-D100Klion-D-100Neo-Penotran
Other names
metronidazole and miconazole nitrate vaginal suppository
02

Targets

CYP51A1 (Sterol 14α-demethylase)Neuraminidase

Beyond the preview

Go deeper on metronidazole + miconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + miconazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call